SCHEMBL106525

SCHEMBL106525

CC(C)(F)c1ccc(C(=O)Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.45
CES1 P23141 2/20 0.45
ALDH1A1 P00352 2/20 0.41
HDAC1 Q13547 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
POLB P06746 1/20 0.40
HSD11B1 P28845 1/20 0.40
SRD5A2 P31213 2/20 0.39
PTPN1 P18031 2/20 0.39
NR4A1 P22736 1/20 0.39
NR4A2 P43354 1/20 0.39
NR4A3 Q92570 1/20 0.39
GSK3B P49841 2/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4114080 0.87 CES2 (0.45) CES2CES1ALDH1A1HDAC1TRPV1
SCHEMBL18130710 0.83 PDE2A (0.44) CES2CES1ALDH1A1HDAC1TRPV1
SCHEMBL7718602 0.82 ESR1 (0.48) CES2CES1ALDH1A1HDAC1POLB
SCHEMBL38841 0.82 HDAC1 (0.59) ALDH1A1HDAC1POLBSRD5A2NPC1
SCHEMBL68177 0.82 CES2 (0.67) CES2CES1TRPV1SRD5A2PTPN1
SCHEMBL10895274 0.80 CES2 (0.46) CES2CES1ALDH1A1TRPV1SRD5A2
SCHEMBL27704404 0.80 ALDH1A1 (0.42) CES2CES1ALDH1A1HDAC1POLB
SCHEMBL10892992 0.80 CES2 (0.46) CES2CES1ALDH1A1TRPV1SRD5A2
SCHEMBL107327 0.80 SRD5A2 (0.61) CES2CES1ALDH1A1SRD5A2NR4A2
SCHEMBL103721 0.78 CES2 (0.50) CES2CES1ALDH1A1SRD5A2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205564-B1 NOVEL KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2014-07-30 EP disclosed
EP-2426109-B1 NOVEL KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2013-12-18 EP disclosed
EP-2426109-A1 NOVEL KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-03-07 EP disclosed
US-7943618-B2 Btk protein kinase inhibitors ROCHE PALO ALTO LLC (US) 2011-05-17 US disclosed
EP-2205564-A1 NOVEL KINASE INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009053269-A1 NOVEL KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 WO disclosed
US-20090105209-A1 BTK protein kinase inhibitors ROCHE PALO ALTO LLC 2009-04-23 US disclosed
EP-1150955-A2 G-PROTEIN COUPLED HEPTAHELICAL RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2001-11-07 EP disclosed
WO-2000046203-A2 G-PROTEIN COUPLED HEPTAHELICAL RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105209-A1 BTK protein kinase inhibitors BTK, SYK, LYN CES2 4490/4885CES1 2638/4885ALDH1A1 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.